Built around your programme
Expert-led decisions, connected data and a practical route to the next meaningful experiment.
Fusion Antibodies provides antibody humanization services that help biotechnology and pharmaceutical companies reduce immunogenicity while preserving the affinity, specificity and functionality of their lead antibodies. Since 2012, we have completed more than 290 antibody humanization projects while 100% successfully maintaining function and affinity and no reported immunogenicity issues following our humanization strategy.
Fusion Antibodies provides antibody humanization services that help biotechnology and pharmaceutical companies reduce immunogenicity while preserving the affinity, specificity and functionality of their lead antibodies. Since 2012, we have completed more than 290 antibody humanization projects while 100% successfully maintaining function and affinity and no reported immunogenicity issues following our humanization strategy.

Our proprietary Humanization CDRx® platform combines advanced CDR grafting, intelligent framework selection and structural modelling to generate highly developable humanized antibodies suitable for therapeutic antibody development. Whether you require humanization of mouse or rabbit antibodies, VHH humanization, or support for more complex antibody formats, our experienced antibody engineering scientists work collaboratively to deliver candidates with an exceptionally high probability of success.
Successful antibody humanization requires more than simply replacing framework residues. Structural compatibility, developability and immunogenicity must all be considered to maximise the likelihood of producing a therapeutic candidate.
Fusion's Humanization CDRx® platform applies a multi-stage workflow that combines advanced computational antibody engineering with extensive scientific expertise.
Every project begins by identifying the most suitable acceptor framework from a proprietary database containing more than 200,000 mature human antibody sequences.
Unlike approaches that rely solely on germline frameworks, our mature framework strategy increases structural compatibility while reducing the risk of introducing unwanted sequence liabilities.
Framework selection is guided by algorithms that evaluate:
This approach enables the preservation of antibody binding while reducing immunogenicity.
Following framework selection, complementarity determining regions (CDRs) are transferred using a precision CDR grafting strategy.
Targeted back-mutations are then introduced only where structural analysis indicates they are required to maintain antibody conformation and antigen recognition.
Each design is informed by knowledge gained from:
The result is a focused set of candidates designed to retain affinity while significantly improving developability.
Each project includes computational analysis to evaluate structural integrity before laboratory testing.
Our reports include:
Rather than generating hundreds of variants, Humanization CDRx® produces a focused panel of 25 optimised candidates (Top 5 heavy chains × Top 5 light chains), reducing downstream screening while optimizing the probability of identifying successful humanized antibodies.
Optional wet-laboratory validation provides in vitro experimental confirmation of antibody expression, functionality and binding performance.

Fusion Antibodies has successfully humanized antibodies originating from numerous species and antibody formats, including:
Our platform also supports specialised applications including:
If your antibody format presents unusual structural challenges, our antibody engineering team develops bespoke humanization strategies tailored to your molecule.
Why Choose Fusion Antibodies for Antibody Humanization?
Humanization CDRx® uses mature human antibody frameworks instead of relying solely on germline sequences, improving structural compatibility and increasing the likelihood of preserving biological activity.
Targeted back-mutations are informed by extensive project experience and structural analysis, helping preserve affinity while minimising unnecessary sequence changes.
Potential sequence liabilities are identified during the design stage, helping reduce risks associated with manufacturability, stability and downstream development.
Our scientists frequently work with antibodies that differ substantially from conventional human IgG molecules, including rabbit antibodies, camelid VHHs and other atypical scaffolds.
A focused panel of rationally designed variants enables efficient laboratory evaluation while avoiding unnecessary experimental screening.
Our antibody humanization services support:
Whether your programme is progressing from antibody discovery into preclinical development or requires optimisation of an existing lead, our scientists can tailor a humanization strategy to meet your objectives.
Antibody humanization is a critical step in transforming promising research antibodies into therapeutic candidates with reduced immunogenicity and improved clinical potential.
Fusion Antibodies combines computational design, antibody engineering expertise and optional laboratory validation to deliver humanized antibodies with a high probability of success.
Talk to our scientists today to discuss your antibody humanization project.
Expert-led decisions, connected data and a practical route to the next meaningful experiment.
Start with the biology, share the context and move forward with confidence.
Yes. Our teams are designed to share context across discovery, engineering and supply.
Share the useful starting details and your enquiry will be sent securely to Fusion’s scientific team.